Chemours Company (The) (CC) Receiving Somewhat Positive Media Coverage, Accern Reports
News articles about Chemours Company (The) (NYSE:CC) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemours Company (The) earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media stories about the specialty chemicals company an impact score of 47.0811517949725 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Chemours Company (The) (CC) versus LyondellBasell Industries NV (LYB) Critical Contrast (americanbankingnews.com)
- The Chemours Company (CC) (footballhebdo.com)
- Chemours Company (The) (CC) PT Raised to $60.00 at Jefferies Group LLC (elcumanes.com)
- Jefferies Group Weighs in on Chemours Company (The)’s FY2018 Earnings (NYSE:CC) (americanbankingnews.com)
- Chemours Company (The) (CC) PT Raised to $55.00 at J P Morgan Chase & Co (americanbankingnews.com)
Shares of Chemours Company (NYSE:CC) opened at 49.31 on Friday. The company has a market capitalization of $9.13 billion, a PE ratio of 32.25 and a beta of 3.63. Chemours Company has a 1-year low of $8.62 and a 1-year high of $49.67. The firm’s 50-day moving average price is $41.37 and its 200 day moving average price is $37.03.
Chemours Company (The) (NYSE:CC) last released its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.02. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.27 EPS. Equities analysts predict that Chemours Company will post $3.31 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 17th will be given a dividend of $0.03 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.24%. Chemours Company (The)’s dividend payout ratio (DPR) is currently 8.11%.
A number of equities research analysts recently issued reports on the company. UBS AG reissued a “sell” rating and set a $36.00 price target (up previously from $35.00) on shares of Chemours Company (The) in a research report on Wednesday, June 14th. J P Morgan Chase & Co increased their price target on Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a research report on Friday. Susquehanna Bancshares Inc increased their price target on Chemours Company (The) from $45.00 to $55.00 and gave the stock a “positive” rating in a research report on Monday, May 15th. Zacks Investment Research downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Citigroup Inc. increased their price target on Chemours Company (The) to $59.00 and gave the stock a “buy” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $44.50.
In other news, VP Erich Parker sold 4,908 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $45.53, for a total transaction of $223,461.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul Kirsch sold 19,036 shares of the business’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $41.42, for a total transaction of $788,471.12. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.
Chemours Company (The) Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.